<DOC>
	<DOCNO>NCT01404234</DOCNO>
	<brief_summary>This open-label , multicenter study child ≤ 12 year age cystic fibrosis ( CF ) chronic Pseudomonas aeruginosa ( PA ) infection lower airway use three 28-day course Aztreonam Inhalation Solution ( AZLI ) 75 mg three time daily , follow 28 day AZLI . The total treatment duration 6 month .</brief_summary>
	<brief_title>Safety AZLI Children With Cystic Fibrosis ( CF ) Chronic Pseudomonas Aeruginosa Lower Airways</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Aztreonam</mesh_term>
	<criteria>Diagnosis CF determine 1997 CF Consensus Conference criterion : Documented sweat chloride ≥ 60 mEq/L quantitative pilocarpine iontophoresis test OR Abnormal nasal transepithelial potential difference ( NPD ) test OR A genotype 2 identifiable mutation consistent CF AND One clinical feature consistent CF . Documented positive low respiratory tract culture PA screen visit plus two document positive low respiratory tract culture PA within 12 month prior study entry ( must minimum 3 month apart . ) Clinically stable evidence significant respiratory symptom , obtain clinical evaluation , chest radiograph finding screen would require administration IV antipseudomonal antibiotic , oxygen supplementation , hospitalization . Use IV inhale antipseudomonal antibiotic within 14 day study entry Presence condition abnormality would compromise participant 's safety quality study data , opinion investigator History sputum throat swab culture yield Burkholderia spp . within 2 year prior screen visit History hypersensitivity/adverse reaction aztreonam History hypersensitivity/adverse reaction betaagonists History lung transplantation Administration investigational drug device within 30 day prior screen visit within 6 halflives investigational drug ( whichever longer ) Hospitalization pulmonaryrelated illness within 28 day prior screen visit Changes initiation chronic azithromycin treatment within 28 day prior screen visit Changes initiation hypertonic saline treatment within 7 day prior screen visit ; subject stable regimen hypertonic saline ( 28 day on/28 day ) , begin end cycle hypertonic saline allow Changes antimicrobial , bronchodilator ( BD ) , corticosteroid dornase alfa medication within 7 day prior screen visit ; Changes physiotherapy technique schedule within 7 day prior screen visit Abnormal renal hepatic function result recent test within previous 90 day</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Cystic fibrosis</keyword>
	<keyword>CF</keyword>
	<keyword>PA</keyword>
	<keyword>Pseudomonas aeruginosa</keyword>
	<keyword>AZLI</keyword>
	<keyword>aztreonam</keyword>
	<keyword>Chronic Pseudomonas aeruginosa</keyword>
</DOC>